Community Practice

AAP endorses new recommendations on dental procedure antibiotics.

Shire recalls some Daytrana (methylphenidate transdermal system) ADHD patches.

Medicare announces it will offer reimbursement for use of infusion pump for subcutaneous immune globulin.

Pharmacists offer opinions on dextromethorphan restrictions in August Drug Topics on-line poll.

ACAM2000 smallpox vaccine receives FDA approval.

ACAM2000 smallpox vaccine receives FDA approval.

Researchers have found that patients that used statin drugs had fewer signs associated with Alzheimer's disease. Statins may impact Alzheimer's patients

University and pharmaceutical firm create program to detect and better understand adverse drug reactions.

Doctors treating cancer patients want CMS to ease rules restricting coverage of anemia drugs.

A drug with a new mechanism of action is always a welcome addition in the fight against HIV. Maraviroc was recently approved by the FDA and is the first of the chemokine receptor 5 antagonists to enter the market.

Several healthcare groups involved in making and dispensing pharmaceuticals have partnered to create Rx Response-a program designed to help support the continued delivery of drugs during a public health emergency.

Reclast (zoledronic acid injection, Novartis) has been approved by the FDA as the first once-yearly treatment for women with postmenopausal osteoporosis.

Information on how genetic variations can affect a patient's response to warfarin must now be included on the drug's label, according to the FDA.

"Fast start, slow finish." That's how Douglas Long characterized the U.S. pharmaceutical market over the past year, ending in June 2007.

The FDA has proposed a new regulation that sets standards for OTC sunscreen products.

CMS has announced its intention to implement a new rule requiring tamper-resistant prescription pads for Medicaid Rxs beginning Oct. 1.

The author calls for a transparent system for reimbursing pharmacists for their drugs and services that takes into account their operating costs and allows for cost-of-dispensing adjustments.

New drug approvals for branded drugs, generics, plus OTCs, home health care, health and beauty, etc.

Updates on the latest technology for pharmacies

Chlorofluorocarbons substances responsible for thinning the ozone layer, have been almost phased out of use. A few uses deemed essential are still allowed, including some inhalers for asthma and chronic obstructive pulmonary disease.

The Consumer Healthcare Products Association is providing educational programs to stop DXM abuse in teens. It also discusses what manufacturers are voluntarily doing to stop teens from purchasing large quantities of cough and cold medicines which contain the ingredients dextromethorphan.

Concerns over the drug diversion and the impact of pharmaceuticals on the environment converge as federal and health experts look for new models to control the impact of unused drugs.

Pharmacists begin to organize into trade associations.

OIG plans to continue their investigation into differences between the retail and chain pharmacy participation in Part D. They intend to examine reimbursements to independent and chain pharmacies for specific drug products and to compare the terms of the contracts offered to chains and independent pharmacies.

New tools are available for independent pharmacies for better business management.

A drug with a new mechanism of action is always a welcome addition in the fight against HIV. Maraviroc was recently approved by the FDA and is the first of the chemokine receptor 5 antagonists to enter the market.

Opinions are divided over how to dispose of unwanted drugs that minimize damage to the environment.

CMS thinks AMP is a reasonable way to reimburse pharmacists for generic drugs if states do their part, but NACDS claims the new methodology pays pharmacists below cost.

Shaughnessy joins AMCP; APhA names new governance director

MSLs provide information and education to insurers and doctors but differ from sales representatives in their ability to provide peer-level interaction.